Last reviewed · How we verify

A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

NCT01715896 Phase 2 COMPLETED Results posted

The primary objectives of this study is to explore the efficacy of mavrilimumab compared with golimumab in the treatment of adult subjects 18-80 years of age with moderate-to-severe active rheumatoid arthritis (RA) who have an inadequate response to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) and/or one or two anti-tumor necrosis factor (TNF) agents (excluding golimumab) for efficacy or safety reasons.

Details

Lead sponsorMedImmune LLC
PhasePhase 2
StatusCOMPLETED
Enrolment215
Start date2013-03
Completion2015-02

Conditions

Interventions

Primary outcomes

Countries

Argentina, Colombia, Czechia, France, Greece, Hungary, Israel, Mexico, Portugal, Russia, Serbia, Slovakia, Spain, United Kingdom